Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage. Is it efficacious? Yes

Area of Science:

• Neurology
• Neurosurgery
• Critical Care Medicine

Background:

• Aneurysmal subarachnoid hemorrhage (SAH) frequently leads to cerebral vasospasm, a major cause of mortality and disability.
• Cerebral blood flow (CBF) is often reduced post-SAH, correlating inversely with clinical severity.
• Hypotension and hypovolemia can worsen reduced CBF, leading to critical hypoperfusion.

Purpose of the Study:

• To review the evidence supporting the use of induced hypertension, hypervolemia, and hemodilution (HHH) therapy in managing cerebral vasospasm following SAH.
• To highlight the potential benefits of HHH therapy in restoring blood flow to ischemic areas and preventing neurological deficits.

Main Methods:

• Review of existing literature and clinical evidence regarding HHH therapy.
• Analysis of the challenges in conducting prospective, randomized trials of HHH therapy, such as blinding difficulties.

Main Results:

• Strong evidence suggests HHH therapy can reverse delayed neurological deficits by improving perfusion in ischemic regions.
• Prophylactic HHH therapy may decrease the incidence and severity of delayed ischemic deficits (DID).

Conclusions:

• HHH therapy is a crucial intervention for managing cerebral vasospasm post-SAH.
• While prospective randomized trials are lacking, existing evidence supports the efficacy of HHH therapy in improving patient outcomes.